Hitachi Energy selected as preferred technology provider for the longest HVDC link in the UK

HVDC interconnection to secure power transmission and support new renewable electricity generation with the country’s largest electricity transmission project

Zurich, Switzerland, July 26, 2023 (GLOBE NEWSWIRE) — Hitachi Energy, a global technology leader that is advancing a sustainable energy future for all, today announced it has been selected as preferred technology provider of SSEN Transmission and National Grid, to supply two high-voltage direct current (HVDC) converter stations to interconnect the Scottish and English power grids.

The energy transition requires a collaborative effort that can only be achieved with advanced technologies and new ways of working. In appointing Hitachi Energy as their preferred technology provider, SSEN Transmission and National Grid secure best-in-class technology and future production capacity in a rapidly growing market. For Hitachi Energy, this enables investment in new production capacity and to undertake large-scale recruitment drives. It also strengthens collaboration, standardization of solutions, and synergies between projects.

The integration of renewables requires solutions that make the grid resilient, stable, and flexible. Hitachi Energy’s innovation and long development of voltage sourced converter (VSC) power electronics and control and protection (MACH™) technologies meet the requirements alongside many other landmark grid integration projects.

Eastern Green Link 2 will consist of two 525-kilovolt (kV) bipole VSC converter stations connected by 440 kilometers of subsea cable and 70 kilometers of underground cable, making it the longest HVDC link in the UK. The link will efficiently supply a total of 2,000 megawatts (MW) of electricity, which is enough to power around two million UK homes.1

The link will help to secure power transmission in the northern UK and support the integration of new renewable electricity generation in Scotland, as part of the UK’s Net Zero Strategy.2 As much as 11,000 MW of offshore wind capacity is possible in Scottish waters by 20303, and HVDC transmission will play a large part in bringing this vast amount of renewable power to shore and south, to communities across the country.

“The UK’s Net Zero Strategy has ambitious targets which will require vast amounts of new renewable generation. Electricity will be the backbone of the entire energy system,” said Niklas Persson, Managing Director at Hitachi Energy’s Grid Integration business. “Our pioneering HVDC technology will ensure that this electricity will reliably and efficiently get where it’s needed most.”

“This is another important milestone for EGL2 which is part of the new network infrastructure required to help the UK meet its net zero and energy security ambitions,” said Sarah Sale, Deputy Project Director of National Grid. “Along with cabling bidder and formal joint venture announcements, this is another key part of the project which is now in place and ready for the delivery phase. We look forward to working in collaboration with Hitachi Energy and BAM as the project continues to progress.”

“The converter stations at either end of the cable will play a crucial role in making the power transported subsea suitable for transportation around the onshore transmission network – getting Hitachi Energy and BAM in place to deliver that technology is great for the project,” said Ricky Saez, the EGL2 Project Director from SSEN Transmission.

“BAM is delighted to work in collaboration with Hitachi Energy on this vital renewable energy project for National Grid and SSEN Transmission,” said Huw Jones, Executive Director of BAM Nuttall. “The converter stations will enable the transmission of green energy from areas of offshore wind generation to centers of population, supporting the UK’s net zero ambitions and providing better energy security. We look forward to engaging with local communities and suppliers in Aberdeenshire and North Yorkshire, supporting BAM’s vision to deliver sustainable infrastructure for our clients, stakeholders, and the communities in which we work.”

Hitachi Energy is collaborating with BAM, a construction company that designs, builds, and maintains sustainable buildings and infrastructure, to provide the civil and installation scope for the project. The collaboration with BAM will leverage the core competencies of the two companies to deliver a best-in-class solution for the project.

Hitachi Energy pioneered commercial HVDC technology almost 70 years ago and has delivered more than half of the world’s HVDC projects.

1 https://www.nationalgrid.com/electricity-transmission/network-and-infrastructure/segl2
2 https://www.gov.uk/government/publications/net-zero-strategy
3 https://www.gov.scot/publications/offshore-wind-policy-statement/
4 Modular Advanced Control for HVDC (MACH™)

HVDC website:

https://www.hitachienergy.com/offering/product-and-system/hvdc

Photo captions:

North Sea Link Blyth Converter Station UK

Eastern Green Link 2

About Hitachi Energy
Hitachi Energy is a global technology leader that is advancing a sustainable energy future for all. We serve customers in the utility, industry and infrastructure sectors with innovative solutions and services across the value chain. Together with customers and partners, we pioneer technologies and enable the digital transformation required to accelerate the energy transition towards a carbon-neutral future. We are advancing the world’s energy system to become more sustainable, flexible and secure whilst balancing social, environmental and economic value. Hitachi Energy has a proven track record and unparalleled installed base in more than 140 countries. Headquartered in Switzerland, we employ around 40,000 people in 90 countries and generate business volumes of over $10 billion USD.
https://www.hitachienergy.com
https://www.linkedin.com/company/hitachienergy
https://twitter.com/HitachiEnergy

About Hitachi, Ltd.

Hitachi drives Social Innovation Business, creating a sustainable society through the use of data and technology. We solve customers’ and society’s challenges with Lumada solutions leveraging IT, OT (Operational Technology) and products. Hitachi operates under the business structure of “Digital Systems & Services” – supporting our customers’ digital transformation; “Green Energy & Mobility” – contributing to a decarbonized society through energy and railway systems, and “Connective Industries” – connecting products through digital technology to provide solutions in various industries. Driven by Digital, Green, and Innovation, we aim for growth through co-creation with our customers. The company’s consolidated revenues for fiscal year 2022 (ended March 31, 2023) totaled 10,881.1 billion yen, with 696 consolidated subsidiaries and approximately 320,000 employees worldwide. For more information on Hitachi, please visit the company’s website at https://www.hitachi.com.

Attachments

Jocelyn Chang
Hitachi Energy
jocelyn.chang@hitachienergy.com

GlobeNewswire Distribution ID 8881044

Curia étend ses capacités dans le domaine des produits biologiques en accédant à l’ADN doggybone de Touchlight

Curia collabore avec Touchlight afin d’élargir son offre de fabrication d’ARNm pour permettre l’accès à l’ADN enzymatique doggybone (dbDNA™)

ALBANY, New York, et Hampton, Royaume-Uni, 25 juill. 2023 (GLOBE NEWSWIRE) — Curia, une organisation de premier plan dans le domaine de la recherche, du développement et de la fabrication en sous-traitance, et Touchlight, une société pionnière dans la production enzymatique d’ADN, ont annoncé aujourd’hui un accord qui fournira à Curia ainsi qu’à ses clients un moyen simplifié d’accès à l’ADN doggybone de Touchlight (dbDNA). L’arrangement étend les offres de fabrication d’ARNm de Curia avec une source supplémentaire et différenciée de matière première d’ADN qui est immédiatement accessible par les clients de Curia. Dans le cadre de l’accord, Touchlight fabriquera directement dbDNA pour le compte des clients de Curia.

« Curia reste déterminée à renforcer ses offres de produits biologiques et ses capacités de fabrication d’ARNm de bout en bout », a déclaré Christopher Conway, président de la R&D chez Curia. « Avec l’ajout de l’ADN enzymatique grâce à notre partenariat avec Touchlight, nos clients bénéficieront d’un avantage décisif en termes d’évolutivité et de rapidité de commercialisation. »

dbDNA de Touchlight est un vecteur d’ADN linéaire, à double brin, fermé de manière covalente. L’ADN sert de modèle pour l’élaboration des traitements à base d’ARNm. Grâce à un processus enzymatique simple appelé transcription in vitro, les informations génétiques sont copiées de l’ADN à l’ARNm. Cet ARNm est alors capable d’apprendre aux cellules à fabriquer des protéines spécifiques qui sont utilisées pour soigner ou prévenir des maladies. L’ADN enzymatique de Touchlight est produit par un processus enzymatique acellulaire qui offre des avantages inégalés en termes de rapidité, de qualité et de capacité par rapport à la production traditionnelle d’ADN plasmidique.

Karen Fallen, PDG de Touchlight, a commenté : « Nous sommes ravis de travailler avec Curia afin d’élargir l’accès à dbDNA en tant que matière de départ essentielle. Travailler en parallèle avec d’autres CDMO est un élément clé de notre volonté de permettre un large accès du marché à dbDNA. Curia met en place une solution complète pour l’ARNm, et cet accord permet aux deux entreprises d’étendre leur offre à un public plus large. »

dbDNA de Touchlight est une solution nouvelle, largement applicable et polyvalente, qui permet à Curia de renforcer ses capacités de fabrication d’ARNm en complément de son offre de plasmides de qualité bioprocédurale.

À propos de Curia

Curia est une une organisation de recherche, développement et fabrication en sous-traitance de premier plan qui fournit des produits et services allant de la R&D aux clients pharmaceutiques et biopharmaceutiques en passant par la fabrication commerciale. Basés sur 29 sites à travers les États-Unis, l’Europe et l’Asie, les près de 4 000 employés de Curia aident les clients de l’entreprise à passer de la curiosité à la guérison. Pour en savoir plus, rendez-vous sur CuriaGlobal.com.

À propos de Touchlight

Touchlight est une CDMO privée basée à Londres, au Royaume-Uni, qui se concentre sur la prestation de services d’ADN et la fabrication d’ADN doggybone (dbDNA™) produit de manière enzymatique pour permettre le développement de médicaments génétiques. Touchlight assure le développement et la fabrication rapides et enzymatiques d’ADN pour la production de tous les traitements avancés, comprenant l’ARNm, la thérapie génique virale et non virale, et l’API d’ADN. dbDNA est une structure minimale, linéaire et fermée de façon covalente, qui élimine les séquences bactériennes. La plateforme révolutionnaire de production enzymatique de Touchlight permet une vitesse et une échelle sans précédent, et offre la possibilité de cibler des gènes d’une taille et d’une complexité impossibles à atteindre avec les technologies actuelles. Les clients peuvent bénéficier d’une assistance depuis la phase préclinique jusqu’à l’octroi de licence et au transfert de technologie pour une utilisation en interne, en passant par le développement et l’approvisionnement.

Contact chez Curia :
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

Contact chez Touchlight :

Karen Fallen, présidente-directrice générale
Robin Bodicoat, directeur du marketing
E : info@touchlight.com
T : +44 20 8481 9200

GlobeNewswire Distribution ID 8880042

Curia expande sua capacidade biológica com acesso ao DNA doggybone da Touchlight

Curia colabora com a Touchlight para expandir sua oferta de produção de mRNA para permitir o acesso ao DNA enzimático de doggybone (dbDNA™)

ALBANY, N.Y. e HAMPTON, Reino Unido, July 25, 2023 (GLOBE NEWSWIRE) — A Curia, uma organização líder em contratação de pesquisa, desenvolvimento e fabricação, e a Touchlight, uma empresa pioneira na produção de DNA enzimático, anunciou hoje um acordo de fornecimento para a Curia e seus clientes de um acesso arrojado ao DNA doggybone (dbDNA) da Touchlight. O acordo expande as ofertas de produção de mRNA da Curia com uma fonte adicional diferenciada de matéria-prima de DNA imediatamente disponível para ser acessada pelos clientes da Curia. Sob o acordo, a Touchlight passará a produzir o dbDNA diretamente em nome dos clientes da Curia.

“A Curia continua empenhada a aprimorar nossas ofertas biológicas e capacidade de manufatura completa de mRNA”, disse Christopher Conway, presidente de P&D da Curia. “Com a adição do DNA enzimático por meio da nossa parceria com a Touchlight, nossos clientes terão uma vantagem essencial em termos de escalabilidade e velocidade no mercado.”

O dbDNA da Touchlight é um vetor de DNA linear, de fita dupla e fechado covalentemente. O DNA serve como modelo para terapias de mRNA. Através de um processo enzimático simples chamado transcrição in vitro, a informação genética é copiada do DNA para o mRNA. Este mRNA é então capaz de ensinar as células a produzir proteínas precisas que são usadas para tratar ou prevenir doenças. O DNA enzimático da Touchlight é produzido com um processo enzimático livre de células que oferece benefícios incomparáveis em velocidade, qualidade e capacidade quando comparado à produção tradicional de DNA de plasmídeo.

Karen Fallen, CEO da Touchlight, comentou: “É um grande prazer trabalhar com a Curia na maior expansão do acesso ao dbDNA como um material inicial essencial. O trabalho junto aos outros CDMOs é um componente essencial do nosso foco em permitir amplo acesso ao mercado de dbDNA. A Curia está criando uma solução abrangente de mRNA, e esse acordo permite que ambas as empresas ampliem sua oferta para um público mais amplo.”

O dbDNA da Touchlight é uma nova solução amplamente aplicável e versátil, avançando a capacidade de produção de mRNA da Curia como um complemento à sua oferta de plasmídeo de grau de bioprocessamento.

Sobre a Curia

A Curia é uma organização líder em contratos de pesquisa, desenvolvimento e fabricação que fornece produtos e serviços de P&D por meio da fabricação comercial para clientes farmacêuticos e biofarmacêuticos. Os quase 4.000 funcionários da Curia em 29 locais nos EUA, Europa e Ásia ajudam seus clientes a avançar da curiosidade para a cura. Saiba mais em CuriaGlobal.com.

Sobre a Touchlight

A Touchlight é uma CDMO de propriedade privada com sede em Londres, Reino Unido, focada no fornecimento de serviços de DNA e na fabricação de produtos enzimáticos doggybone DNA (dbDNA™) para permitir o desenvolvimento de medicamentos genéticos. A Touchlight fornece desenvolvimento e fabricação rápidos e enzimáticos de DNA para toda a produção de terapia avançada, incluindo mRNA, terapia gênica viral e não viral e API de DNA. O dbDNA é uma estrutura mínima, linear e covalentemente fechada, que elimina sequências bacterianas. A revolucionária plataforma de produção enzimática da Touchlight permite velocidade, escala e capacidade sem precedentes para o direcionamento de genes com um tamanho e complexidade impossíveis com as tecnologias atuais. Os clientes podem ser apoiados durante a fase pré-clínica, desenvolvimento e fornecimento, até o licenciamento e transferência de tecnologia para uso interno.

Contato da Curia:
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

Contato da Touchlight:

Karen Fallen, Diretora Executiva
Robin Bodicoat, Diretor de Marketing
E: info@touchlight.com
T: +44 (20) 8481 9200

GlobeNewswire Distribution ID 8880042

Curia expands biologics capabilities with access to Touchlight’s doggybone DNA

Curia collaborates with Touchlight to expand its mRNA manufacturing offering to enable access to enzymatic doggybone DNA (dbDNA™)

ALBANY, N.Y. and HAMPTON, United Kingdom, July 24, 2023 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization, and Touchlight, a company pioneering enzymatic DNA production, today announced an agreement which will provide Curia and its clients a streamlined means of access to Touchlight’s doggybone DNA (dbDNA). The arrangement expands Curia’s mRNA manufacturing offerings with an additional differentiated source of DNA raw material that is immediately available to be accessed by Curia customers. Under the arrangement, Touchlight will directly manufacture dbDNA on behalf of Curia’s customers.

“Curia remains committed to strengthening our biologics offerings and end-to-end mRNA manufacturing capabilities,” said Christopher Conway, President of R&D, Curia. “With the addition of enzymatic DNA through our partnership with Touchlight, our customers will have a critical advantage in terms of scalability and speed to market.”

Touchlight’s dbDNA is a linear, double-stranded, covalently-closed DNA vector. DNA serves as the template for making mRNA therapies. Through a simple enzymatic process called in vitro transcription, genetic information is copied from DNA to mRNA. This mRNA is then able to teach the cells to make precise proteins that are used to treat or prevent diseases. Touchlight’s enzymatic DNA is produced with a cell-free enzymatic process that offers unmatched benefits in speed, quality and capacity when compared to traditional plasmid DNA production.

Karen Fallen, CEO, Touchlight commented: “We are delighted to work with Curia in order to further expand access to dbDNA as a critical starting material. Working in parallel with fellow CDMOs is a key component of our focus upon enabling broad market access to dbDNA. Curia is building a comprehensive mRNA solution, and this arrangement enables both companies to extend their offering to a wider audience.”

Touchlight’s dbDNA is a novel solution that is widely applicable and versatile, advancing Curia’s mRNA manufacturing capabilities as a complement to its bioprocessing-grade plasmid offering.

About Curia

Curia is a leading contract research, development, and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers. Curia’s nearly 4,000 employees at 29 locations across the U.S., Europe, and Asia help its customers advance from curiosity to cure. Learn more at CuriaGlobal.com.

About Touchlight

Touchlight is a privately-owned CDMO based in London, U.K., focused on providing DNA services and manufacturing enzymatically produced doggybone DNA (dbDNA™) to enable the development of genetic medicines. Touchlight provides rapid, enzymatic DNA development and manufacturing for all advanced therapy production, including mRNA, viral and non-viral gene therapy, and DNA API. dbDNA is a minimal, linear, covalently closed structure, which eliminates bacterial sequences. Touchlight’s revolutionary enzymatic production platform enables unprecedented speed, scale, and the ability to target genes with a size and complexity that is impossible with current technologies. Clients can be supported from pre-clinical through development and supply to licensing and tech transfer for use in-house.

Curia Contact Information:
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

Touchlight contact information:

Karen Fallen, Chief Executive Officer
Robin Bodicoat, Head of Marketing
E: info@touchlight.com
T: +44 20 8481 9200

GlobeNewswire Distribution ID 8879177

OPEN Health announces a new team of experts will lead its HEOR & Market Access Scientific Office

London, UK, July 24, 2023 (GLOBE NEWSWIRE) — OPEN Health, a global provider of consultancyHEOR and market access, and scientific communications services, today announced a new team of experts will lead its HEOR & Market Access Scientific Office. This expert team will be led by Dr. Elisabeth Fenwick as Chief Scientific Officer with support from Professor Ben van Hout as Scientific Founder.

Both Elisabeth and Ben joined OPEN Health through its acquisition of Pharmerit International. Elisabeth Fenwick is most widely known for working on the cost-effectiveness acceptability curve (CEAC), creating the cost-effectiveness acceptability frontier, and for her work in value of information analyses for research decisions. She has over 20 years of experience in the industry and has published more than 50 publications globally. Ben van Hout is most commonly known for being one of the co-founders of the EQ-5D (a standardized measure of health-related quality of life) and as the developer of the CEAC. He was also one of the first researchers to perform a discrete event simulation and is published in the New England Journal of Medicine. He has over 35 years of experience in the industry and was honored with the ISPOR Avedis Donabedian Outcomes Research Lifetime Achievement Award in 2020.

“The purpose of the Scientific Office is to ensure that science is at the center of everything we do. Our scientific experts are here to support the HEOR and market access team with their amazing research developing innovative solutions.” Elisabeth commented.

The Scientific Office is made up of experts who bring unique skillsets from across OPEN Health’s HEOR & market access service areas. The appointed team consists of Maarten Treur, MSc, Vice President and Global Head of Modeling & Meta-Analysis; Dr. Viktor Chirikov, Director of Real‑World Evidence & Data Analytics; Dr. Marco Boeri, Director of Preference Research in Patient-Centered Outcomes; and Emanuele Arcà, MSc, Senior Research Consultant in Strategic Market Access. Craig Bennison, MSc, Executive Director and Global Innovation Lead for OPEN Health HEOR & Market Access, will also join the team and will focus specifically on innovation.

“Over the last few years, the scientific contributions and leadership of these experts have played instrumental roles in shaping our reputation and research efforts, working in partnership with our clients to improve health outcomes and patient wellbeing,” said Richard Jones, President of OPEN Health Evidence & Access. “This team will ensure our scientific expertise, thought leadership, and innovation stay front and center of our HEOR and market access offering.”

To learn more about the team of experts in the Scientific Office, please explore this interactive publication.

About OPEN Health

OPEN Health unites deep scientific knowledge with wide-ranging specialist expertise to unlock possibilities that improve health outcomes and patient wellbeing. Working in partnership with our clients, we embrace our different perspectives and strengths to deliver fresh thinking and solutions that make a difference. OPEN Health is a flexible global organization that solves complex healthcare challenges across HEOR and market access, medical communications and creative omnichannel campaigns. For more information on OPEN Health, visit www.openhealthgroup.com.

Candice Subero
OPEN Health
candicesubero@openhealthgroup.com

GlobeNewswire Distribution ID 8878752